According to a recent study performed on an Australian cohort of SSc patients, the presence of anti-Ro52 antibodies represents an independent prognostic factor for mortality, and a risk factor for the development of PAH, independently from ILD occurrence [48]. Here, TRIM21 is linked to interstitial lung disease.